% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koelsche:128928,
      author       = {C. Koelsche and M. Renner and P. Johann$^*$ and I.
                      Leiss$^*$ and F. Sahm$^*$ and S. Schimmack and E. Wardelmann
                      and E.-K. Renker and P. Schirmacher and A. Korshunov$^*$ and
                      A. von Deimling$^*$ and G. Mechtersheimer},
      title        = {{D}ifferential nuclear {ATRX} expression in sarcomas.},
      journal      = {Histopathology},
      volume       = {68},
      number       = {5},
      issn         = {0309-0167},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2017-04940},
      pages        = {738 - 745},
      year         = {2016},
      abstract     = {Nuclear α-thalassemia/mental retardation X-linked (ATRX)
                      loss and alternative lengthening of telomeres (ALT) are
                      linked in distinct malignancies. We therefore aimed to
                      determine the nuclear ATRX expression correlated with ALT in
                      a comprehensive series of sarcomas.A total of 573
                      formalin-fixed paraffin-embedded sarcomas comprising 28
                      entities were investigated for nuclear ATRX expression by
                      immunohistochemistry. Telomere-specific fluorescence in-situ
                      hybridization (FISH) was used to determine the ALT phenotype
                      in 50 sarcomas with complete or heterogeneous ATRX loss.
                      Complete nuclear ATRX loss was detected in 58 of 573
                      sarcomas, all high-grade, with the highest prevalence in
                      undifferentiated pleomorphic sarcomas $(38\%)$ and
                      pleomorphic liposarcomas $(38\%),$ followed by
                      dedifferentiated liposarcomas $(24\%),$ osteosarcomas
                      $(21\%),$ leiomyosarcomas $(17\%),$ myxofibrosarcomas
                      $(11\%)$ and malignant peripheral nerve sheath tumours
                      $(4\%).$ Interestingly, a further 20 sarcomas, all belonging
                      to the aforementioned entities with complete ATRX loss,
                      presented with a heterogeneous ATRX expression pattern. ALT
                      was observed in 41 of 42 sarcomas with complete ATRX loss,
                      but only in two of eight sarcomas with heterogeneous
                      expression.Nuclear ATRX loss, either complete or
                      heterogeneous, is encountered in a considerable number of
                      high-grade sarcomas with non-specific genetic alterations. A
                      causal relationship with ALT might be indicated at least in
                      cases with a complete nuclear ATRX loss.},
      cin          = {G380 / B062 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)G380-20160331 / I:(DE-He78)B062-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26291601},
      doi          = {10.1111/his.12812},
      url          = {https://inrepo02.dkfz.de/record/128928},
}